Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 5th edition, 486 pages Free download

Lung Cancer

Free Subscription 02.11.2020 2 Am J Clin Oncol 1 Ann Surg Oncol 4 Ann Thorac Surg 3 Anticancer Res 3 BMC Cancer 2 Br J Cancer 2 Cancer 2 Cancer Res 6 Cancer Sci 7 Carcinogenesis 1 Chest 1 Clin Lung Cancer 1 Eur J Cancer 1 Eur J Cardiothorac Surg 1 Eur Respir J 3 Hum Pathol 1 J Clin Oncol 1 J Thorac Cardiovasc Surg 23 J Thorac Oncol 1 JAMA Oncol 1 Lancet Oncol 1 Lung Cancer 2 Lung Cancer (Auckl) 1 N Engl J Med 1 Nat Med 2 Oncol Rep 1 Oncologist 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. MACARI DM, Gbadamosi B, Jaiyesimi I, Gaikazian S, et al
   Medical Cannabis in Cancer Patients: A Survey of a Community Hematology Oncology Population.
   Am J Clin Oncol. 2020;43:636-639.
   PubMed         Abstract available
   
   
2. DONG S, Liang J, Zhai W, Yu Z, et al
   Development and Validation of an Individualized Nomogram for Predicting Overall Survival in Patients With Typical Lung Carcinoid Tumors.
   Am J Clin Oncol. 2020;43:607-614.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. EBY M, Seder CW
   Reply to "Letter to the editor of Annals of Surgical Oncology Concerning " The Landmark Series: Multimodality Therapy for Stage 3A Non-small Cell Lung Cancer" by Sunil Kumar et al.
   Ann Surg Oncol. 2020 Oct 26. pii: 10.1245/s10434-020-09258.
   PubMed        
   
   

   
   Ann Thorac Surg

4. CLARAMUNT NP, Cypel M
   Video-Assisted Thoracic Surgery as the Future of Pulmonary Metastasectomy: Reply.
   Ann Thorac Surg. 2020;110:1096-1097.
   PubMed        
   
   
5. SHRAGER JB
   New Information on Talc and Mesothelioma.
   Ann Thorac Surg. 2020;110:1099.
   PubMed        
   
   
6. GERACI TC, Ferrari-Light D, Cerfolio RJ
   Questioning the Value of Sentinel Lymph Node Mapping in Non-Small Cell Lung Cancer: Reply.
   Ann Thorac Surg. 2020;110:1436-1437.
   PubMed        
   
   
7. PERENTES JY, Zellweger M, Gonzalez M
   Change of Paradigm in Pulmonary Metastasectomy.
   Ann Thorac Surg. 2020;110:1096.
   PubMed        
   
   

   
   Anticancer Res

8. LEE SY, Slagle-Webb B, Sharma AK, Connor JR, et al
   Characterization of a Novel Barbituric Acid and Two Thiobarbituric Acid Compounds for Lung Cancer Treatment.
   Anticancer Res. 2020;40:6039-6049.
   PubMed         Abstract available
   
   
9. NAGASHIMA T, Oshima T, Hiroshima Y, Yokose T, et al
   Clinical Significance of Tumour CD44v and MIST1 Expression in Patients With Non-small-cell Lung Cancer.
   Anticancer Res. 2020;40:6407-6416.
   PubMed         Abstract available
   
   
10. SJOGREN K, Jacobsen KA, GrOnberg BH, Halvorsen TO, et al
    Timing of Severe Toxicity from Chemotherapy in Patients With Lung Cancer.
    Anticancer Res. 2020;40:6399-6406.
    PubMed         Abstract available
    
    

    
    BMC Cancer

11. KOGO M, Fujimoto D, Hosoya K, Nagata K, et al
    Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study.
    BMC Cancer. 2020;20:104.
    PubMed         Abstract available
    
    
12. PARK JY, Lee YJ, Kim T, Lee CY, et al
    Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea.
    BMC Cancer. 2020;20:1040.
    PubMed         Abstract available
    
    
13. TOKUDOME N, Koh Y, Akamatsu H, Fujimoto D, et al
    Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.
    BMC Cancer. 2020;20:103.
    PubMed         Abstract available
    
    

    
    Br J Cancer

14. YANG L, Zhou F, Zhuang Y, Liu Y, et al
    Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.
    Br J Cancer. 2020 Oct 30. pii: 10.1038/s41416-020-01135.
    PubMed         Abstract available
    
    
15. HANSEN MS, Licaj I, Braaten T, Lund E, et al
    The fraction of lung cancer attributable to smoking in the Norwegian Women and Cancer (NOWAC) Study.
    Br J Cancer. 2020 Oct 27. pii: 10.1038/s41416-020-01131.
    PubMed         Abstract available
    
    

    
    Cancer

16. WANG M, Liang H, Wang W, Zhao S, et al
    Immune-related adverse events of a PD-(L)1 inhibitor plus chemotherapy versus a PD-(L)1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
    Cancer. 2020 Oct 29. doi: 10.1002/cncr.33270.
    PubMed         Abstract available
    
    
17. PATHAK R, De Lima Lopes G, Yu H, Aryal MR, et al
    Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
    Cancer. 2020 Oct 29. doi: 10.1002/cncr.33269.
    PubMed         Abstract available
    
    

    
    Cancer Res

18. STARRETT JH, Guernet AA, Cuomo ME, Poels KE, et al
    Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations.
    Cancer Res. 2020;80:2017-2030.
    PubMed         Abstract available
    
    
19. LIU CH, Chen Z, Chen K, Liao FT, et al
    Lipopolysaccharide-mediated chronic inflammation promotes tobacco carcinogen-induced lung cancer and determines the efficacy of immunotherapy.
    Cancer Res. 2020 Oct 29. pii: 0008-5472.CAN-20-1994.
    PubMed         Abstract available
    
    

    
    Cancer Sci

20. SATA M, Sasaki S, Oikado K, Saito Y, et al
    Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
    Cancer Sci. 2020 Oct 30. doi: 10.1111/cas.14715.
    PubMed         Abstract available
    
    
21. XIE W, Wang Y, Zhang Y, Xiang Y, et al
    SNP rs4142441 and MYC co-modulated lncRNA OSER1-AS1 suppresses non-small cell lung cancer by sequestering ELAVL1.
    Cancer Sci. 2020 Oct 28. doi: 10.1111/cas.14713.
    PubMed         Abstract available
    
    
22. WAKABAYASHI Y, Masuda T, Fujitaka K, Nakashima T, et al
    Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer.
    Cancer Sci. 2020 Oct 26. doi: 10.1111/cas.14711.
    PubMed         Abstract available
    
    
23. SAITO Y, Sasaki S, Oikado K, Tominaga J, et al
    Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer.
    Cancer Sci. 2020 Oct 24. doi: 10.1111/cas.14710.
    PubMed         Abstract available
    
    
24. FURUYA N, Matsumoto S, Kakinuma K, Morikawa K, et al
    Feasibility of transbronchial brushing cytology specimens for next generation sequencing in peripheral lung cancer.
    Cancer Sci. 2020 Oct 30. doi: 10.1111/cas.14714.
    PubMed         Abstract available
    
    
25. MIYAWAKI T, Wakuda K, Kenmotsu H, Miyawaki E, et al
    Proposing Synchronous Oligometastatic Non-Small Cell Lung Cancer Based on Progression after First-line Systemic Therapy.
    Cancer Sci. 2020 Oct 23. doi: 10.1111/cas.14707.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

26. HU H, Zhang Q, Chen W, Wu T, et al
    MicroRNA-301a promotes pancreatic cancer invasion and metastasis through the JAK/STAT3 signaling pathway by targeting SOCS5.
    Carcinogenesis. 2020;41:502-514.
    PubMed         Abstract available
    
    
27. HUANG T, Guo YZ, Yue X, Zhang GP, et al
    Cripto-1 promotes tumor invasion and predicts poor outcomes in hepatocellular carcinoma.
    Carcinogenesis. 2020;41:571-581.
    PubMed         Abstract available
    
    
28. HUANG T, Guo YZ, Yue X, Zhang GP, et al
    Cripto-1 promotes tumor invasion and predicts poor outcomes in hepatocellular carcinoma.
    Carcinogenesis. 2020;41:571-581.
    PubMed         Abstract available
    
    
29. LI L, Hu C, Lu C, Zhang K, et al
    Applied electric fields suppress osimertinib-induced cytotoxicity via inhibiting FOXO3a nuclear translocation through AKT activation.
    Carcinogenesis. 2020;41:600-610.
    PubMed         Abstract available
    
    
30. LIU YJ, Chang YJ, Kuo YT, Liang PH, et al
    Targeting beta-tubulin/CCT-beta complex induces apoptosis and suppresses migration and invasion of highly metastatic lung adenocarcinoma.
    Carcinogenesis. 2020;41:699-710.
    PubMed         Abstract available
    
    
31. SAAD MI, McLeod L, Yu L, Ebi H, et al
    The ADAM17 protease promotes tobacco smoke carcinogen-induced lung tumorigenesis.
    Carcinogenesis. 2020;41:527-538.
    PubMed         Abstract available
    
    
32. LUO J, Xu X
    Dietary fiber intake and the risk of bladder cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cohort.
    Carcinogenesis. 2019 Nov 18. pii: 5628148. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Chest

33. LANG M, Yeung T, Shepard JO, Sharma A, et al
    Operational challenges of a low-dose CT lung cancer screening program during the COVID-19 pandemic.
    Chest. 2020 Oct 26. pii: S0012-3692(20)35095-9. doi: 10.1016/j.chest.2020.
    PubMed        
    
    

    
    Clin Lung Cancer

34. SPIGEL DR, Jotte RM, Aix SP, Gressot L, et al
    Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30270.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

35. CHORTI E, Kanaki T, Zimmer L, Hadaschik E, et al
    Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Eur J Cancer. 2020;131:18-26.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

36. HOYOS MEJIA L, Romero Roman A, Gil Barturen M, Cordoba Pelaez MDM, et al
    Thoracic surgery during the coronavirus disease 2019 (COVID-19) pandemic in Madrid, Spain: single-centre report.
    Eur J Cardiothorac Surg. 2020;58:991-996.
    PubMed         Abstract available
    
    

    
    Eur Respir J

37. GAGA M, Chorostowska-Wynimko J, Horvath I, Tammemagi MC, et al
    Validation of Lung EpiCheck(R), a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals.
    Eur Respir J. 2020 Oct 29. pii: 13993003.02682-2020.
    PubMed         Abstract available
    
    

    
    Hum Pathol

38. CHEN L, Cao MF, Xiao JF, Ma QH, et al
    Stromal PD-1(+) tumor-associated macrophages predict poor prognosis in lung adenocarcinoma.
    Hum Pathol. 2020;97:68-79.
    PubMed         Abstract available
    
    
39. PAAJANEN J, Laaksonen S, Kettunen E, Ilonen I, et al
    Histopathological features of epithelioid malignant pleural mesotheliomas in patients with extended survival.
    Hum Pathol. 2020;98:110-119.
    PubMed         Abstract available
    
    
40. MORAN CA, Lindholm KE, Brunnstrom H, Langman G, et al
    Typical and atypical carcinoid tumors of the lung: a clinicopathological correlation of 783 cases with emphasis on histological features.
    Hum Pathol. 2020;98:98-109.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

41. BURNS TF, Borghaei H, Ramalingam SS, Mok TS, et al
    Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.
    J Clin Oncol. 2020 Oct 26:JCO2000744. doi: 10.1200/JCO.20.00744.
    PubMed        
    
    

    
    J Thorac Cardiovasc Surg

42. BOTT MJ
    Commentary: Opioid dependence in the lobectomy patient: A hard pill to swallow.
    J Thorac Cardiovasc Surg. 2020;159:703-704.
    PubMed        
    
    

    
    J Thorac Oncol

43. FRIEDBERG JS, Culligan MJ, Tsao AS, Rusch V, et al
    Reply to Waller et al. Standardizing Surgical Treatment for Mesothelioma.
    J Thorac Oncol. 2020;15:e75-e77.
    PubMed        
    
    
44. WALLER DA, Bilancia R, Bille A, Tenconi S, et al
    Standardizing Surgical Treatment of Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2020;15:e73-e74.
    PubMed        
    
    
45. WANG Z, Duan J, Wang J, Wang G, et al
    In Reply: A Modified Algorithm Adjusting Both High and Minor Allele-Frequency to Redefine Blood-Based Tumor Mutational Burden for Optimal Prediction of Clinical Benefits From Programmed Cell Death-Protein 1 Immunotherapy.
    J Thorac Oncol. 2020;15:e72-e73.
    PubMed        
    
    
46. LIU Z, Xie Z, Cai X, He J, et al
    A Modified Algorithm Adjusting Both High and Minor Allele Frequency Mutation to Redefine Blood-Based Tumor Mutational Burden (bTMB) for Optimal Prediction of Clinical Benefits From Immune Checkpoint Inhibitor Therapy.
    J Thorac Oncol. 2020;15:e69-e72.
    PubMed        
    
    
47. PEIKERT T
    Personalized Oncolytic Therapy: The Next Step Toward the Successful Clinical Application of Vaccine-Strain Measles Viruses for Cancer Therapy?
    J Thorac Oncol. 2020;15:689-691.
    PubMed        
    
    
48. ZHENG MM, Li YS, Tu HY, Jiang BY, et al
    Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated non-small cell lung cancer.
    J Thorac Oncol. 2020 Oct 26. pii: S1556-0864(20)30816.
    PubMed         Abstract available
    
    
49. DENG L, Cheng H
    Uncommon as an Individual, Not That Uncommon as a Whole.
    J Thorac Oncol. 2020;15:681-685.
    PubMed        
    
    
50. YASUDA H
    Targeting Co-Occurring Genomic Alterations in MET Exon 14 Skipping Mutation-Positive NSCLC.
    J Thorac Oncol. 2020;15:679-680.
    PubMed        
    
    
51. CARBONE M, Green JB, Bucci EM, Lednicky JA, et al
    Coronaviruses: Facts, Myths, and Hypotheses.
    J Thorac Oncol. 2020;15:675-678.
    PubMed        
    
    
52. DE MIGUEL FJ
    An Elaborate STING Operation to Take Down NSCLC: Combination of Immunotherapies and Chemotherapies.
    J Thorac Oncol. 2020;15:686-688.
    PubMed        
    
    
53. WO Y, Wang Y, Lu T, Sun D, et al
    Evaluated Lymph Node Number in Population-Based Analyses: Significant Prognostic Factor, but Assess With Caution.
    J Thorac Oncol. 2020;15:e77-e78.
    PubMed        
    
    
54. NAGASAKA M, Ou SI
    Is NRG2alpha Fusion a "Doppelganger" to NRG1alpha/beta Fusions in Oncology?
    J Thorac Oncol. 2020;15:878-880.
    PubMed        
    
    
55. REMON J, Reguart N, Garcia-Campelo R, Conde E, et al
    Lung Cancer in Spain.
    J Thorac Oncol. 2020 Oct 24. pii: S1556-0864(20)30812.
    PubMed        
    
    
56. AUJAYEB A, Taylor L
    Is the Deciduoid Variant of Pleural Mesothelioma Significant?
    J Thorac Oncol. 2020;15:e94.
    PubMed        
    
    
57. ARAI S, Yano S
    In Reply.
    J Thorac Oncol. 2020;15:e93.
    PubMed        
    
    
58. CORTINOVIS D, Gemelli M, Cappuzzo F
    Alectinib Resistance Through Amphiregulin Overexpression: Is Osimertinib the Best Candidate?
    J Thorac Oncol. 2020;15:e92-e93.
    PubMed        
    
    
59. HASSAN R, Sengupta M, Murai J, Pommier Y, et al
    Response to Letter to the Editor by Yang et al.
    J Thorac Oncol. 2020;15:e91.
    PubMed        
    
    
60. YANG H, Xu D, Gao Y, Schmid RA, et al
    The Association of BAP1 Loss-of-Function With the Defect in Homologous Recombination Repair and Sensitivity to PARP-Targeted Therapy.
    J Thorac Oncol. 2020;15:e88-e90.
    PubMed        
    
    
61. MAZZOTTA M, Marinelli D, Maugeri-Sacca M
    KEAP1-NFE2L2 Mutations in NSCLC: Increased Awareness Needed. Reply to "KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis".
    J Thorac Oncol. 2020;15:e87-e88.
    PubMed        
    
    
62. ZHANG C, Zhang C, Li J, Wang H, et al
    KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis.
    J Thorac Oncol. 2020;15:e85-e86.
    PubMed        
    
    
63. DAGOGO-JACK I, Lennerz JK
    Personalized Diagnostic Workflows: The Next Wave of Precision Medicine in NSCLC.
    J Thorac Oncol. 2020;15:888-890.
    PubMed        
    
    
64. CARBONE M
    Transitional Mesothelioma and Artificial Intelligence: Do We Need One More Subtype? and Do We Need Computers to Identify Them?
    J Thorac Oncol. 2020;15:884-887.
    PubMed        
    
    
65. NICHOLSON AG, Sauter JL, Galateau-Salle F
    In Reply.
    J Thorac Oncol. 2020;15:e94-e95.
    PubMed        
    
    

    
    JAMA Oncol

66. SHANKAR B, Zhang J, Naqash AR, Forde PM, et al
    Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Oct 29. pii: 2772169. doi: 10.1001/jamaoncol.2020.5012.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

67. REDMAN MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, et al
    Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
    Lancet Oncol. 2020 Oct 27. pii: S1470-2045(20)30475.
    PubMed         Abstract available
    
    

    
    Lung Cancer

68. FAEHLING M, Schumann C, Christopoulos P, Hoffknecht P, et al
    Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP).
    Lung Cancer. 2020;150:114-122.
    PubMed         Abstract available
    
    

    
    Lung Cancer (Auckl)

69. NAGATA I, Ogino T, Arimura T, Yoshiura T, et al
    Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer.
    Lung Cancer (Auckl). 2020;11:105-111.
    PubMed         Abstract available
    
    
70. LEE CS, Sharma S, Miao E, Mensah C, et al
    A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity.
    Lung Cancer (Auckl). 2020;11:73-103.
    PubMed         Abstract available
    
    

    
    N Engl J Med

71. PLANCHARD D
    Adjuvant Osimertinib in EGFR-Mutated Non-Small-Cell Lung Cancer.
    N Engl J Med. 2020;383:1780-1782.
    PubMed        
    
    

    
    Nat Med

72. BRASTIANOS PK, Lee EQ, Cohen JV, Tolaney SM, et al
    Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
    Nat Med. 2020;26:1280-1284.
    PubMed         Abstract available
    
    

    
    Oncol Rep

73. PARK WH
    Propyl gallate reduces the growth of lung cancer cells through caspasedependent apoptosis and G1 phase arrest of the cell cycle.
    Oncol Rep. 2020 Oct 20. doi: 10.3892/or.2020.7815.
    PubMed         Abstract available
    
    
74. CUI XY, Park SH, Park WH
    Auranofin inhibits the proliferation of lung cancer cells via necrosis and caspasedependent apoptosis.
    Oncol Rep. 2020 Oct 21. doi: 10.3892/or.2020.7818.
    PubMed         Abstract available
    
    

    
    Oncologist

75. HOLLEN PJ, Gralla RJ, Gentzler RD, Hall RD, et al
    Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation.
    Oncologist. 2020 Oct 23. doi: 10.1002/onco.13571.
    PubMed         Abstract available
    
    

    
    PLoS One

76. CHANIAD P, Trakunran K, Geater SL, Keeratichananont W, et al
    Serum miRNAs associated with tumor-promoting cytokines in non-small cell lung cancer.
    PLoS One. 2020;15:e0241593.
    PubMed         Abstract available
    
    
77. GU JJ, Hoj J, Rouse C, Pendergast AM, et al
    Mesenchymal stem cells promote metastasis through activation of an ABL-MMP9 signaling axis in lung cancer cells.
    PLoS One. 2020;15:e0241423.
    PubMed         Abstract available
    
    
78. TONG J, Krieger JR, Taylor P, Bagshaw R, et al
    Cancer proteome and metabolite changes linked to SHMT2.
    PLoS One. 2020;15:e0237981.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: